Online citations, reference lists, and bibliographies.
← Back to Search

Pemetrexed In The Treatment Of Malignant Mesothelioma: Results From An Expanded Access Program In Germany.

M. Reck, R. Stahel, J. von Pawel, M. Karthaus, S. Korfee, M. Serke, W. Schuette, C. Eschbach, T. Fink, Monika I. Leschinger, C. Manegold
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). Chemonaïve and pretreated patients with inoperable MM of the pleura or peritoneum were eligible. This report describes the results obtained in German centers. Investigators could choose between three treatments: Pemetrexed 500 mg/m(2) alone (P) or in combination with cisplatin 75 mg/m(2) (PC) or carboplatin AUC 5 (PCb). From November 2002 to June 2004, a total of 567 patients (554 with pleural MM; 41% pretreated) were included. Of 548 evaluable patients with pleural MM, 191 received P, 137 PC and 220 PCb. Patients in the P group were more often pretreated (70%) and had worse performance status compared with the other groups. In the P, PC, and PCb groups overall response rate (ORR) was 16%, 24% and 18%, median time to progression (TTP) was 5.5, 8.2, and 6.9 months, and median overall survival (OS) was 8.7, 11.3 and 9.7 months respectively. Efficacy outcomes were better for chemonaïve than for pretreated patients, and P was less hematotoxic than PC or PCb. Treatment of pleural MM with pemetrexed alone or in combination with platinum was safe and active as first and second-line therapy.
This paper references
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
Pemetrexed þ/ platinum for patients with malignant peritoneal mesothelioma: the Bielefeld experience
M Karthaus (2006)
10.1007/BF02967383
New guidelines to evaluate the response to treatment in solid tumors
P. Therasse (2000)
10.1016/S1556-0864(15)30351-8
Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program
P. Jänne (2006)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
10.1002/JSO.20266
Malignant peritoneal mesothelioma
K. Bani-Hani (2005)
10.1016/J.EJSO.2006.03.012
Comprehensive management of diffuse malignant peritoneal mesothelioma.
P. Sugarbaker (2006)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.3109/9781439802014-13
Malignant mesothelioma.
B. Robinson (2005)
10.1080/14774003.2005.11667666
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
Tim J. Carter (2005)
10.1016/S1556-0864(15)31509-4
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.1999.17.10.3009
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
R. Thödtmann (1999)
10.3816/CLC.2005.N.020
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.
P. Jänne (2005)
10.1016/J.LUNGCAN.2006.09.023
Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
C. Obasaju (2007)
[Malignant mesothelioma of the tunica vaginalis].
J. Uría González-Tova (2000)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1177/030089160509100315
Malignant Pericardial Mesothelioma. Report of two Cases, Review of the Literature and Differential Diagnosis
M. Papi (2005)
10.1097/JTO.0b013e31817c73ec
Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
Paul Taylor (2008)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1097/JTO.0B013E31802F3813
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)



This paper is referenced by
10.1016/J.DCJWKP.2011.10.005
Therapie des nicht-resektablen malignen Pleuramesothelioms
Monika Serke (2011)
10.1159/000464410
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma
M. Mencoboni (2017)
10.1016/j.lungcan.2011.01.005
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
G. Pasello (2011)
10.1080/14737140.2016.1220305
Preventing recurrence of diffuse malignant peritoneal mesothelioma
Joshua C. Leinwand (2016)
10.18773/AUSTPRESCR.2011.076
Medical management of mesothelioma
R. Bowman (2011)
10.1515/pterid-2015-0015
Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: a case report and review of the literature
Hana Študentová (2016)
10.1093/jjco/hyz104
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Y. Nagata (2019)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
10.1016/B978-0-7020-3369-8.00013-6
Chapter 13 – Pleura and chest wall
B. Corrin (2011)
10.1002/cncr.26497
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma
S. Kao (2012)
10.1245/s10434-019-08139-4
Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series
Joshua C. Leinwand (2019)
In vitro testing of drug sensitivity in tumor cells from effusion
Carl-Olof Hillerdal (2017)
10.3904/KJM.2014.87.6.756
Case of Malignant Mesothelioma of the Peritoneum and Pleura
Su Jin Lee (2014)
10.2169/internalmedicine.4809-20
Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome.
Yuka Ide (2020)
10.1007/s10405-011-0503-9
Das fortgeschrittene Lungenkarzinom
M. Pless (2011)
10.3390/molecules23123138
Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft
Vanessa Izquierdo-Sánchez (2018)
10.18632/oncotarget.20889
Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
Carl-Olof Hillerdal (2017)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
10.1016/j.ncrna.2018.11.001
Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
B. Biersack (2018)
Semantic Scholar Logo Some data provided by SemanticScholar